Skip to content
FrontierPicks

Watching

PRCT · PROCEPT BioRobotics

Conviction · Low · not more likely to lead the S&P 500 over the next three months

Note written ·

The last three months

Up 16.2% since the close; the S&P 500 is down 9.4% over the same sessions. Figures in the note can cover a different window.

PRCT daily closes from 24 August 2026 to 20 November 2026, last $24.70, with its price line set under the older rule: a daily close above $27.70; 50-day average $19.87 on 20 November 2026. 24 August 2026: $21.25; 50-day average $20.4925 August 2026: $21.60; 50-day average $20.4126 August 2026: $21.07; 50-day average $20.3627 August 2026: $20.60; 50-day average $20.3328 August 2026: $20.83; 50-day average $20.3331 August 2026: $21.20; 50-day average $20.321 September 2026: $20.91; 50-day average $20.322 September 2026: $21.97; 50-day average $20.353 September 2026: $21.37; 50-day average $20.364 September 2026: $22.76; 50-day average $20.388 September 2026: $21.35; 50-day average $20.369 September 2026: $20.74; 50-day average $20.3210 September 2026: $20.07; 50-day average $20.2711 September 2026: $20.38; 50-day average $20.2114 September 2026: $21.02; 50-day average $20.2115 September 2026: $19.30; 50-day average $20.1716 September 2026: $19.44; 50-day average $20.1417 September 2026: $19.47; 50-day average $20.1318 September 2026: $19.30; 50-day average $20.1221 September 2026: $18.51; 50-day average $20.0822 September 2026: $18.43; 50-day average $20.0223 September 2026: $18.09; 50-day average $20.0024 September 2026: $17.50; 50-day average $19.9625 September 2026: $17.20; 50-day average $19.9228 September 2026: $17.25; 50-day average $19.8829 September 2026: $18.22; 50-day average $19.8630 September 2026: $18.22; 50-day average $19.861 October 2026: $17.02; 50-day average $19.842 October 2026: $17.16; 50-day average $19.845 October 2026: $17.82; 50-day average $19.866 October 2026: $17.51; 50-day average $19.867 October 2026: $17.91; 50-day average $19.858 October 2026: $17.90; 50-day average $19.859 October 2026: $18.40; 50-day average $19.8612 October 2026: $19.57; 50-day average $19.8813 October 2026: $19.10; 50-day average $19.8914 October 2026: $17.51; 50-day average $19.8815 October 2026: $18.15; 50-day average $19.8516 October 2026: $17.57; 50-day average $19.8119 October 2026: $18.28; 50-day average $19.7620 October 2026: $18.82; 50-day average $19.7021 October 2026: $18.27; 50-day average $19.6122 October 2026: $20.03; 50-day average $19.5923 October 2026: $19.96; 50-day average $19.5526 October 2026: $19.83; 50-day average $19.5127 October 2026: $19.80; 50-day average $19.4928 October 2026: $20.20; 50-day average $19.4629 October 2026: $20.30; 50-day average $19.4330 October 2026: $19.20; 50-day average $19.402 November 2026: $19.44; 50-day average $19.363 November 2026: $20.17; 50-day average $19.334 November 2026: $21.66; 50-day average $19.345 November 2026: $20.27; 50-day average $19.326 November 2026: $20.62; 50-day average $19.329 November 2026: $22.37; 50-day average $19.3510 November 2026: $23.05; 50-day average $19.3911 November 2026: $23.34; 50-day average $19.4412 November 2026: $23.51; 50-day average $19.4713 November 2026: $23.80; 50-day average $19.5216 November 2026: $23.54; 50-day average $19.5317 November 2026: $23.78; 50-day average $19.5818 November 2026: $25.18; 50-day average $19.6719 November 2026: $25.75; 50-day average $19.7820 November 2026: $24.70; 50-day average $19.87

Daily closes, to . Red: the note's price line under the older rule, a daily close above $27.70, set on 19 November 2026. The pale line is the 50-day average, $19.87 on .

Price line

A daily close above $27.70, 10% over the 18 November 2026 close, which would show the shares extending their lead; or full-year 2026 revenue reported at the $410 million top of the reaffirmed range.

A price line, set under the rules before kill lines became business results on 20 November 2026. It stays until the note's next read replaces it; a close through it only makes the note due for a fresh read.

Research onlyNot in the portfolio.

The portfolio's record →

The business · as of

PROCEPT BioRobotics sells the HYDROS robotic system, which uses a water jet (Aquablation) to treat enlarged prostates. Hospitals buy or rent the system, then buy a single-use handpiece and other consumables for each procedure, plus service. Revenue was $98.3 million in the quarter to 30 September 2026.

What is changing, and what follows · as of

What is changing now
On 4 November 2026 the company reported third-quarter revenue of $98.3 million, up 18% but below estimates. It reaffirmed 2026 revenue of $390–410 million and said procedures would land near the low end of 54,000–56,000.
What follows for the company
Gross margin was 66% and operating expenses rose to $92.5 million. The company targets positive adjusted EBITDA in the fourth quarter of 2026, with $218 million of cash and short-term investments at 30 September 2026.
What follows for its customers, suppliers and competitors
Faster Aquablation adoption takes patients from Boston Scientific (BSX) Rezum and Teleflex (TFX) UroLift. Management said on 4 November 2026 that competitive dynamics did not change in the quarter.

What the price assumes · as of

At the 18 November 2026 close (filed inputs to 4 November 2026) the shares trade at 3.6 times sales and 4.4 times book value, for an enterprise value of $1,282 million. P/E and EV/EBIT are not meaningful because the company loses money. The price holds only if revenue keeps growing near the 18% of the latest filed quarter while the −27.9% operating margin narrows toward break-even.

Key figures from the filings · Health Care

Quarter to 30 September 2026, filed 4 November 2026; valuation at the 20 November 2026 close

The last six quarters

Revenue, its change on a year and gross and operating margin over the six quarters to 30 September 2026, from the company's filings with the SEC, the latest filed 4 November 2026.
Revenue, latest quarter ($M)
98.3
Revenue, change on a year (%)
+18.0
Gross margin (%)
66.3
Operating margin (%)
−27.9
Free cash flow, four quarters ($M)
−85.1
Net cash, cash less debt ($M)
167
Enterprise value to sales (×)
3.6
Free-cash-flow yield (%)
−6.0
All filed numbers

What PROCEPT BioRobotics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .

Results by quarter Each quarter with the day its figures were first filed, and the day of a later filing that changed them
Quarter to Revenue ($M) On a year (%) Gross margin (%) Operating margin (%)
first filed 98.3 +18.0 66.3 −27.9
first filed 94.5 +19.3 66.0 −29.0
first filed 83.1 +20.2 64.9 −39.2
first filed 76.4 +11.9 60.6 −40.6
first filed 83.3 +42.8 64.8 −27.8
first filed 79.2 +48.4 65.4 −28.0
Income Quarter to 30 September 2026, filed 4 November 2026
Pre-tax income ($M) −26.6
Net income ($M) four quarters: −115 −26.5
Diluted shares, change on a year (%) against the quarter to 30 September 2025 +2.9
Cash flow Four quarters to 30 September 2026, filed 4 November 2026
Operating cash flow ($M) −76.7
Capital spending ($M) 8.4
Free cash flow ($M) −85.1
Balance sheet At 30 September 2026, filed 4 November 2026
Cash and short-term investments ($M) 218
Debt ($M) long-term debt 51.8
Net cash, cash less debt ($M) 167
Deferred revenue ($M) +46.6% on a year 15.6
Backlog, orders not yet delivered ($M) Not reported
Receivables ($M) 105
Inventory ($M) 81.4
Shareholders' equity ($M) 329
Valuation At the 20 November 2026 close, filed figures to 4 November 2026
Market value ($M) 1,421
Enterprise value, market value plus net debt ($M) 1,255
Enterprise value to sales (×) 3.6
Enterprise value to operating income (×) Not meaningful
Price to earnings (×) Not meaningful
Price to book value (×) 4.3
Free-cash-flow yield (%) −6.0

Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 13.7% of shares outstanding sold short, 9.0 days of average trading to cover, +4.8% since the previous report.

Insiders' open-market trades SEC Form 4, by trade date
Window Bought Sold
90 days Not available yet Not available yet
12 months Not available yet Not available yet

Linked companies · as of

Competitors:
BSX, TFX

The thesis

PROCEPT BioRobotics is more likely to lag the S&P 500 over the next three months. Third-quarter revenue missed estimates and procedures are tracking to the low end of guidance. Even so, the shares closed at $25.18 on 18 November 2026, above every analyst target published after the report. The fourth-quarter report, expected in early 2027, shows whether the reaffirmed $390–410 million revenue range for 2026 was within reach.

The company reported third-quarter 2026 revenue of $98.3 million on 4 November 2026. That was up 18% from $83.3 million a year earlier but below the $102.6 million consensus estimate that GuruFocus reported. Revenue for the first nine months was $275.9 million. To land in the reaffirmed range, the fourth quarter has to be the company's largest quarter by a wide margin. On the 4 November 2026 call, Chief Financial Officer Kevin Waters said full-year US procedures should land near 54,000, the bottom of the 54,000–56,000 range. He also said several system placements had slipped into the fourth quarter because of shipping timing.

The rating is Low because the shares have already moved up while the results that would justify the move are still a quarter away. The shares rose 21.4% in the three months to 18 November 2026 and now trade above their 200-day moving average. The call would be wrong if the fourth quarter delivers the revenue range together with the positive adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) that management is targeting.

Bullish and bearish views on PROCEPT BioRobotics Corporation

The bull case on PROCEPT BioRobotics Corporation (PRCT), in brief: consumables grow with every procedure. The bear case: revenue missed and procedures slowed.

Bull case

  • Consumables grow with every procedure. US handpiece and consumable revenue rose 21% to $53.9 million in the third quarter of 2026. US procedures were above 13,400, up about 22% from a year earlier, and the average handpiece price rose 12% to about $3,570 (earnings release, 4 November 2026).
  • Installed base keeps widening. The company delivered 62 US HYDROS systems in the quarter. Of these, 42 were new placements at an average price of about $495,000, which lifted the US installed base to 858 systems from 718 at the end of 2025 (earnings release, 4 November 2026).
  • Management guides to profit by one measure. On the 4 November 2026 call, management said the company is on track for positive adjusted EBITDA in the fourth quarter of 2026. Gross margin was 66.3% in the September 2026 quarter, against 64.8% a year earlier (10-Q filed 4 November 2026).
  • International sales are growing faster. International revenue was a record $12.5 million in the third quarter of 2026, up 32% from $9.4 million a year earlier (earnings release, 4 November 2026).
  • A trial could open a second market. WATER IV compares Aquablation with surgical removal of the prostate in men with prostate cancer and is fully enrolled with 280 patients. On the 4 November 2026 call, Chief Executive Larry Wood said the primary results remain on track for the American Urological Association meeting in May 2027.

Bear case

  • Revenue missed and procedures slowed. Third-quarter revenue of $98.3 million fell short of the $102.6 million consensus estimate (GuruFocus, 4 November 2026). Procedure guidance now points to the low end of 54,000–56,000 (earnings call, 4 November 2026).
  • System sales have stalled. US system sales and rentals were $24.7 million in the third quarter of 2026, flat from a year earlier. Placements at hospitals without a system fell short of plan, which management attributed largely to timing (earnings release and call, 4 November 2026).
  • Losses and cash burn continue. The net loss widened to $26.5 million in the quarter from $21.4 million a year earlier, as operating expenses rose to $92.5 million from $77.2 million (earnings release, 4 November 2026). Free cash flow was negative $85 million over the four quarters to 30 September 2026 (10-Q filed 4 November 2026).
  • Growth slows in 2027. On the 4 November 2026 call, Waters described about 20% revenue growth as the starting point for 2027 planning, against the 27–33% guided for 2026.
  • The price sits above analysts' targets. After the report, Truist raised its target to $24 and UBS to $21 (both 6 November 2026), and Leerink Partners raised its target to $22 (5 November 2026). All three firms kept neutral ratings, and all three targets are below the 18 November 2026 close of $25.18.
  • An insider sold near the post-report low. Chief Strategy and Marketing Officer Pooja Sharma sold 4,710 shares on the open market at $19.71 on 6 November 2026 (SEC Form 4).

Price setup · as of

The shares closed at $25.18 on 18 November 2026, up from $23.78 the session before. They were $23.34 on 11 November 2026. On 6 November 2026, two days after the report, the Form 4 sale above was made at $19.71, so the shares have recovered sharply since that session. Based on adjusted daily closes to 18 November 2026, the last close is above both the 50-day moving average of $19.67 and the 200-day moving average of $22.83. The shares are up 21.4% from the 3-month reference close of $20.74 on 20 August 2026.

On the downside, the 200-day average is the level the case turns on. A return below it would erase the post-report recovery. On the upside, the shares remain 33.9% below the 52-week high of $38.11, set intraday on 5 December 2025, and well above the 52-week closing low of $16.69 on 24 July 2026.

A common market view is that a stock far below its high after a revenue miss keeps lagging. Tests on ten years of US stocks have found no reliable effect so far for stocks after large one-day moves or deep falls from a peak. Across liquid US stocks, the standard deviation of three-month returns was 27% in 2026, so a 21.4% move over three months is within the normal range for a single stock.

Catalysts ahead

  • 2 December 2026: Management fireside discussion at the Piper Sandler 38th Annual Healthcare Conference. This is the first public update since the 4 November 2026 report on whether the system placements that slipped are landing in the fourth quarter and whether procedures are holding near 54,000.
  • ~24 February 2027 (est.): Fourth-quarter and full-year 2026 results, with 2027 guidance. These results show whether revenue reached the reaffirmed $390–410 million range and adjusted EBITDA turned positive, and whether 2027 guidance holds near the 20% growth starting point.
  • ~15 May 2027 (est.): WATER IV primary results at the American Urological Association annual meeting, May 2027. The trial decides whether Aquablation can move into prostate cancer treatment, a market beyond the company's current enlarged-prostate business.

What it trades with · as of

The shares trade on procedure counts and hospital capital spending. Consumables tie revenue to procedures. System revenue depends on hospital capital budgets, and US system revenue was flat in the third quarter of 2026. For patients with an enlarged prostate, the company competes with Boston Scientific's Rezum and Teleflex's UroLift. On the 4 November 2026 call, Wood said competitive dynamics did not change in the quarter. The company is unprofitable and burning cash, so the shares tend to move with small-cap medical-device growth stocks more than with large, profitable device makers. Diluted shares outstanding rose 2.9% from a year earlier in the quarter to 30 September 2026 (10-Q filed 4 November 2026).

The evidence, claim by claim (8)
  1. Third-quarter 2026 revenue was $98.3 million, up 18% from $83.3 million a year earlier; net loss was $26.5 million against $21.4 million. Third-quarter 2026 earnings release, 8-K filed 4 November 2026 · as of
  2. US handpiece and consumable revenue rose 21% to $53.9 million; US system sales and rentals were flat at $24.7 million; US procedures were above 13,400, up about 22%. Third-quarter 2026 earnings release, 8-K filed 4 November 2026 · as of
  3. The company delivered 62 US HYDROS systems, 42 of them new placements, bringing the US installed base to 858 from 718 at the end of 2025. Third-quarter 2026 earnings release, 8-K filed 4 November 2026 · as of
  4. The company reaffirmed 2026 guidance: revenue of $390–410 million, US procedures of 54,000–56,000, and an adjusted EBITDA loss of $30–35 million. Revenue for the first nine months was $275.9 million. Third-quarter 2026 earnings release, 8-K filed 4 November 2026 · as of
  5. The CFO said procedures should land near the low end of guidance, that adjusted EBITDA should turn positive in the fourth quarter, and that about 20% revenue growth is the 2027 planning starting point. Third-quarter 2026 earnings call, 4 November 2026 · as of
  6. Cash and short-term investments were $218 million and long-term debt was $52 million; free cash flow was negative $85 million over four quarters. Form 10-Q for the third quarter of 2026 · as of
  7. Truist kept its Hold rating and raised its target to $24 from $21; UBS kept its Neutral rating and raised its target to $21 from $20. Truist and UBS research notes, 6 November 2026 · as of
  8. Chief Strategy and Marketing Officer Pooja Sharma sold 4,710 shares on the open market at $19.71. SEC Form 4 filed 6 November 2026 · as of

Sources

Related · shared themes

Every buy and sale, with its reason, is published in the portfolio feed. Follow the portfolio feed → Follow @frontierpicks on X